Photoimmunotherapy: Targeting Cancer Cells with Light and Antibodies

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Shimadzu has been collaborating with Dr. Hisataka Kobayashi* of the National Cancer Institute (NCI) in his efforts to develop a revolutionary cancer therapy which selectively kills targeted cancer cells while keeping surrounding healthy cells intact by using conjugate of antibody plus the photo-absorber and near-infrared light. Many Shimadzu analytical solutions are employed in this study, including triple quadrupole mass spectrometry, liquid chromatography, spectrophotometry, high-resolution scanning probe microscopy, and near-infrared fluorescence imaging. Watch the videos and read the related articles to learn more about how the instruments are being used to improve the safety and efficacy of the therapy.

NHK World-Japan
Cancer Immunotherapy: Targeting Tumors with Light and Antibodies

Watch on NHK World-Japan

Press Release
Rakuten Medical and Shimadzu Corporation announce a joint development and commercialization agreement on a medical device to be used with the IlluminoxTM platform

Read More